Pricing Log in Create free account

AnaptysBio, Inc. (ANAB) vs Taysha Gene Therapies, Inc. (TSHA)

AnaptysBio, Inc. and Taysha Gene Therapies, Inc. are both Biotechnology companies. AnaptysBio, Inc. and Taysha Gene Therapies, Inc. are of similar size ($1.4B and $1.3B). AnaptysBio, Inc. grew revenue faster over the last twelve months: 107.7% against 19.0%. Taysha Gene Therapies, Inc. has the higher net margin (0.00% vs −11.5%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, AnaptysBio, Inc. leads on 11 and Taysha Gene Therapies, Inc. on 4.

Valuation

Metric ANAB TSHA Biotechnology median
P/E n/m n/m 10.60
P/S 5.73 136.10 9.40
P/B 104.50 4.15 2.13
Price to free cash flow 302.14 n/m 25.18
EV/EBITDA 26.10 n/m 0.66
EV/Sales 4.51 101.67 9.02
Earnings yield (1.83%) (9.66%) (32.88%)
Free cash flow yield 0.33% (8.66%) (23.13%)

Profitability

Metric ANAB TSHA Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin 17.56% 0.00% 0.00%
Net margin (11.53%) 0.00% 0.00%
Free cash flow margin 1.90% 0.00% 0.00%
Return on equity (114.55%) (47.05%) (51.96%)
Return on assets (7.13%) (37.23%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ANAB TSHA Biotechnology median
Revenue growth (TTM) 107.73% 18.96% 6.76%
EPS growth (last fiscal year) 91.02% 5.56% 29.88%
Revenue growth, 5-year CAGR 25.62% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ANAB TSHA Biotechnology median
Debt to equity 0.00 0.13 0.00
Current ratio 7.58 17.76 4.97
Net debt to EBITDA (6.84) 2.47 1.01

Dividend

Metric ANAB TSHA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ANAB TSHA Biotechnology median
Market cap 1.36b 1.33b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack